Mainz Biomed (NASDAQ:MYNZ) Short Interest Update

Mainz Biomed (NASDAQ:MYNZ) was the target of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 128,500 shares, a growth of 61.2% from the February 28th total of 79,700 shares. Currently, 6.1% of the company’s shares are sold short. Based on an average daily volume of 214,900 shares, the short-interest ratio is currently 0.6 days.

Institutional Trading of Mainz Biomed

An institutional investor recently bought a new position in Mainz Biomed stock. Virtu Financial LLC acquired a new stake in Mainz Biomed (NASDAQ:MYNZ) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 18,330 shares of the company’s stock, valued at approximately $79,000. Virtu Financial LLC owned 0.92% of Mainz Biomed as of its most recent filing with the Securities & Exchange Commission.

Analysts Set New Price Targets

Separately, Maxim Group assumed coverage on Mainz Biomed in a research note on Friday, February 14th. They issued a “buy” rating and a $14.00 price target on the stock.

Mainz Biomed Stock Down 9.8 %

MYNZ traded down $0.39 during midday trading on Friday, hitting $3.58. The company had a trading volume of 263,338 shares, compared to its average volume of 96,360. The stock’s 50 day moving average price is $5.40 and its 200 day moving average price is $7.35. Mainz Biomed has a 52 week low of $3.29 and a 52 week high of $45.20. The company has a market capitalization of $7.16 million, a price-to-earnings ratio of -0.05 and a beta of 0.33.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.